Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (TERRANOVA)
A Randomised, Double-blind, Double Dummy, 56 Week Placebo-controlled, Multicentre, Parallel Group, Phase 3 Study Evaluating Efficacy/Safety of 3 Benralizumab Doses in Patients With Moderate to Very Severe COPD With Previous Exacerbations.
Sponsor: AstraZeneca
A PHASE3 clinical study on Moderate to Very Severe Chronic Obstructive Pulmonary Disease, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 14 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
14 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE3
-
Oct 2025 — Nov 2025 [monthly]
Completed PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
▶ Show 9 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jul 2019 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Dec 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE3
-
Mar 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Jun 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- MedImmune LLC
For direct contact, visit the study record on ClinicalTrials.gov .